Abstract:Positron Emission Tomography (PET) is a rapidly expanding, cutting edge technology for preclinical evaluation, cancer diagnosis and staging, and patient management. A one-step aqueous (18)F-labeling method, which can be applied to peptides to provide functional in vivo images, has been a long-standing challenge in PET imaging. Over the past few years, we have sought a rapid and mild radiolabeling method based on the aqueous radiosynthesis of in vivo stable aryltrifluoroborate (ArBF(3)(-)) conjugates. Recent access to production levels of (18)F-Fluoride led to a fluorescent-(18)F-ArBF(3)(-) at unprecedentedly high specific activities of 15Ci/μmol. However, extending this method to labeling peptides as imaging agents has not been explored.In order to extend these results to a peptide of clinical interest in the context of production-level radiosynthesis, we applied this new technology for labeling RGD, measured its specific activity by standard curve analysis, and carried out a preliminary evaluation of its imaging properties.RGD was labeled in excellent radiochemical yields at exceptionally high specific activity (~14Ci/μmol) (n = 3). Preliminary tumor-specific images corroborated by ex vivo biodistribution data with blocking controls show statistically significant albeit relatively low tumor uptake along with reasonably high tumor:blood ratios (n = 3).Isotope exchange on a clinically useful (18)F-ArBF(3)(-) radiotracer leads to excellent radiochemical yields and exceptionally high specific activities while the anionic nature of the aryltrifluoroborate prosthetic results in very rapid clearance. Since rapid clearance of the radioactive tracer is generally desirable for tracer development, these results suggest new directions for varying linker arm composition to slightly retard clearance rather than enhancing it.This work is the first to use production levels of (18)F-activity to directly label RGD at specific activities that are an order of magnitude higher than most reports and thereby increases the distribution window for radiotracer production and delivery.

Fluorine-18 Labeled Rare-Earth Nanoparticles for Positron Emission Tomography (PET) Imaging of Sentinel Lymph Node.

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

Fluorine-18-labeled Gd3+/Yb3+/Er3+ Co-Doped NaYF4 Nanophosphors for Multimodality PET/MR/UCL Imaging.

Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design.

18F-Labeled Magnetic-Upconversion Nanophosphors Via Rare-Earth Cation-Assisted Ligand Assembly.

Difluorocarbene-enabled synthesis of 18 F-radiotracers in positron emission tomography

New Methods and Techniques for F-18-Labeled Radiopharmaceuticals

Methodological Progress of 18 F-labeled Aromatic PET Radiotracers

Microfluidics for synthesis of peptide-based PET tracers.

Ultrafast synthesis of fluorine-18 doped bismuth based upconversion nanophosphors for tri-modal CT/PET/UCL imaging in vivo.

[18F]sufex Click Chemistry Enabled Ultrafast Late-stage Radiosynthesis

Ultrafast Synthesis of Fluorine-18 Doped Bismuth Based Upconversion Nanophosphors for Tri-Modal CT/PET/UCL Imaging in Vivo

Chelator-Free Labeling of Metal Oxide Nanostructures with Zirconium-89 for Positron Emission Tomography Imaging.

Dual Mode Fluorescent Pet Tracers: Efficient Modular Synthesis, Facile F-18-Radiolabelling, in Vivo Pet Imaging and Ex Vivo Fluorescence

Arene radiofluorination enabled by photoredox-mediated halide interconversion

One-step 18F Labeling of Biomolecules Using Organotrifluoroborates

Automated Microfluidic Chip System for Radiosynthesis of PET Imaging Probes

68Ga-labeled amphiphilic polymer nanoparticles for PET imaging of sentinel lymph node metastasis

Radioisotope Post-Labeling Upconversion Nanophosphors for in Vivo Quantitative Tracking.

A broadly applicable [18F]trifluoromethylation of aryl and heteroaryl iodides for PET imaging

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.